Gland Pharma Limited chart

Last update: 2022-06-03
Key statistics and financials
Revenue per share 268.08
Dividend & YieldN/A₹ (N/A)
Beta N/A
Market capitalization 480.56B
Operating cash flow 7.91B
ESG Scores unknown

Company description

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Sector: Healthcare - Industry: Drug Manufacturers—General

Financial Ratios
Quick Ratio8.02
Working Capital0.23
Return On Equity0.17
Debt To Equity0
Fixed Asset Ratio0
Fixed Interest Cover267.05

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities 1.13B -2.15B 1.43B 658.46M
Total Cashflows From Investing Activities -3.14B -7.66B -15.24B -10.03B
Net Borrowings -5.07M -6.2M -10.16M -2.52M
Total Cash From Financing Activities -31.24M -68.71M 12.38B 348.98M
Change To Operating Activities -220.15M 596.51M 5.14M -214.91M
Issuance Of Stock 12.42B 12.42B 12.42B 385.52M
Net Income 4.52B 7.73B 9.97B 12.12B
Change In Cash -1.36B -669.05M 3.23B -1.74B
Effect Of Exchange Rate -44.31M 51.09M 35.77M 33.11M
Total Cash From Operating Activities 1.85B 7.01B 6.05B 7.91B
Depreciation 821.2M 945.87M 987.8M 1.1B
Change To Account Receivables -458.96M -805.17M -602.01M -5.27B
Other Cashflows From Financing Activities -26.17M -62.51M -23.31M -34.02M
Change To Netincome 52.24M -865.68M -550.55M -1.38B
Capital Expenditures -1.36B -1.95B -2.29B -5.11B

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development
Income Before Tax 6.86B 9.93B 13.35B 16.19B
Net Income 4.52B 7.73B 9.97B 12.12B
Selling General Administrative 2.24B 2.78B 3.12B 3.39B
Gross Profit 10.8B 14.18B 18.53B 21.96B
Ebit 6.24B 8.61B 12.03B 14B
Operating Income 6.24B 8.61B 12.03B 14B
Interest Expense -26.17M -62.51M -29.11M -52.42M
Income Tax Expense 2.34B 2.2B 3.38B 4.07B
Total Revenue 20.44B 26.33B 34.63B 44.01B
Cost Of Revenue 9.64B 12.15B 16.1B 22.04B
Total Other Income ExpenseNet 618.95M 1.32B 1.31B 2.19B
Net Income From Continuing Ops 4.52B 7.73B 9.97B 12.12B
Net Income Applicable To Common Shares 4.52B 7.73B 9.97B 12.12B

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 6.62B 4.4B 5.93B 6.76B
Total Stockholder Equity 28.62B 36.46B 59.03B 71.58B
Other Current Liabilities 612.83M 643.16M 800.49M 941.41M
Total Assets 35.24B 40.86B 64.96B 78.34B
Common Stock 154.95M 154.95M 163.59M 164.3M
Other Current Assets 1.53B 891.99M 769.81M 2.19B
Retained Earnings 22.56B 30.29B 40.26B
Treasury Stock 16.42M 129.06M 209.71M 71.41B
Cash 2.36B 1.69B 4.92B 30.93B
Total Current Liabilities 5.33B 3.59B 5.13B 5.82B
Other Stockholder Equity 16.42M 129.06M 209.71M 71.41B
Property, Plant, and Equipment 10.53B 11.57B 12.92B 16.8B
Total Current Assets 23.57B 28.46B 51.24B 58.52B
Net Tangible Assets 28.62B 36.46B 59.03B 71.45B
Net Receivables 5.52B 6.64B 7.44B 11.99B
Accounts Payable 4.46B 2.49B 4.01B 4.63B


Insider Transactions

Here are the insider transactions of stock shares related to Gland Pharma Limited:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Adhikari (Ashish)Other at price 7.08 per share.D2022-04-29Director6k
Balaji (P)Other at price 7.08 per share.D2022-04-29UNREPORTED3k
Bavalatii (Iranna S)Other at price 7.08 per share.D2022-04-29UNREPORTED4.5k
Bhartee (Roopak)Other at price 7.08 per share.D2022-04-29UNREPORTED10k
Devi (Renuka A)Other at price 7.08 per share.D2022-04-29UNREPORTED4.5k
Ganipisetty (Sambasivarao)Other at price 7.08 per share.D2022-04-29UNREPORTED4.2k
Jayatheertha (A)Other at price 7.08 per share.D2022-04-29UNREPORTED4.5k
Jyothirlatha (CH)Other at price 7.08 per share.D2022-04-29UNREPORTED2.4k
Kapadia (Huseni)Other at price 7.08 per share.D2022-04-29UNREPORTED900
Kumar (G V K S N)Other at price 7.08 per share.D2022-04-29UNREPORTED2.1k
Kumar (P M Senthil)Other at price 7.08 per share.D2022-04-29UNREPORTED6k
Narayana (Lakshmi P)Other at price 7.08 per share.D2022-04-29UNREPORTED6k
Raju (K V G K)Other at price 7.08 per share.D2022-04-29Director30k
Raju (V N S M V G)Other at price 7.08 per share.D2022-04-29UNREPORTED3.9k
Rao (K S V Ramachandra)Other at price 7.08 per share.D2022-04-29UNREPORTED3.6k
Rao (N L Prabhakar)Other at price 7.08 per share.D2022-04-29UNREPORTED2.1k
Rao (Srinivasa D)Other at price 7.08 per share.D2022-04-29UNREPORTED2.1k
Sadu (Srinivasa)Other at price 7.08 per share.D2022-04-29Director (Executive)70.04k
Sahay (Shilpi)Other at price 7.08 per share.D2022-04-29Director4.2k
Sathiyanarayanan (S)Other at price 7.08 per share.D2022-04-29UNREPORTED6k
Shaw (Ashok Kumar)Other at price 7.08 per share.D2022-04-29UNREPORTED4.2k
Venkatesan (C S)Other at price 7.08 per share.D2022-04-29Director20k
Venkateshwaralu (Bommedi)Other at price 7.08 per share.D2022-04-29UNREPORTED900
Shaw (Ashok Kumar)Sale at price 43.13 per share.D2022-03-31UNREPORTED250
Suresh (S)Sale at price 43.07 per share.D2022-03-31UNREPORTED3k
Devi (Renuka A)Sale at price 43.36 per share.D2022-03-30UNREPORTED700
Sridevi (S)Sale at price 43.32 per share.D2022-03-30Director (Executive)7k
Kumar (P Sampath)Sale at price 43.38 per share.D2022-03-29Director (Executive)280
Sridevi (S)Sale at price 43.60 per share.D2022-03-29Director (Executive)1k
Devi (Renuka A)Sale at price 42.65 per share.D2022-03-28UNREPORTED1.2k
Kumar (P Sampath)Sale at price 42.50 per share.D2022-03-28UNREPORTED1.3k
Raju (B S N)Sale at price 42.59 per share.D2022-03-28UNREPORTED454
Sridevi (S)Sale at price 42.36 per share.D2022-03-28UNREPORTED5.75k
Kumar (P Sampath)Sale at price 43.13 per share.D2022-03-23UNREPORTED100
Devi (Renuka A)Sale at price 43.29 per share.D2022-03-16UNREPORTED200
Venkateshwaralu (Bommedi)Sale at price 46.88 per share.D2022-02-11UNREPORTED475
Gland Celsus Bio Chemicals Pvt.Ltd.D2022-01-05Promoter10.05M
Devi (Renuka A)Sale at price 53.06 per share.D2021-12-30UNREPORTED100
Ganipisetty (Sambasivarao)Sale at price 53.09 per share.D2021-12-30UNREPORTED1k
Raja (Lenin Kumar)Sale at price 53.03 per share.D2021-12-30UNREPORTED643
Rao (Srinivasa S)Sale at price 52.98 per share.D2021-12-30UNREPORTED1k
Satyanarayana (T V)Sale at price 53.06 per share.D2021-12-30UNREPORTED250
Satyanarayana (T V)Sale at price 53.21 per share.D2021-12-30UNREPORTED450
Shaw (Ashok Kumar)Sale at price 53.05 per share.D2021-12-30UNREPORTED750
Varma (P B Ravindra)Sale at price 53.05 per share.D2021-12-30UNREPORTED1.5k
Balaji (P)Sale at price 52.15 per share.D2021-12-29UNREPORTED500
Kapadia (Huseni)Sale at price 52.52 per share.D2021-12-29UNREPORTED100
Rao (Srinivasa S)Sale at price 52.58 per share.D2021-12-29UNREPORTED500
Bhartee (Roopak)Sale at price 51.77 per share.D2021-12-27UNREPORTED400
Rao (Raghuramachandra K)Sale at price 51.87 per share.D2021-12-27UNREPORTED1k
Varma (P B Ravindra)Sale at price 52.16 per share.D2021-12-27UNREPORTED14

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Gland Pharma Limited. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Gland Pharma Limited

Here is the result of two systematic investment strategies applied to Gland Pharma Limited. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Gland Pharma Limited

The following chart shows the equity curve of the two systematic investment strategies applied to Gland Pharma Limited:

Gland Pharma Limited automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -10.82% on the backtest period.

Performance at glance

Performance

-10.82 %

Latent gain

-1115.9 ₹

Invested capital

10313.0 ₹

Annualized return

-8.32 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Gland Pharma Limited

This is the result of two momentum investment strategies applied to Gland Pharma Limited. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Gland Pharma Limited

The following chart shows all the entries opened by the momentum investment system on Gland Pharma Limited:

Gland Pharma Limited momentum entries
  • The first momentum investment strategy would give -7.76% of return on Gland Pharma Limited. That represents -773.45₹ of latent gain with 9970.55₹ of employed capital.
  • The second momentum investment strategy would give -21.94% of return on Gland Pharma Limited. That represents -1723.4₹ of latent gain with 7854.8₹ of employed capital.
Performance at glance (1Q Momentum)

Performance

-7.76 %

Latent gain

-773.45 ₹

Invested capital

9970.55 ₹

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

-21.94 %

Latent gain

-1723.4 ₹

Invested capital

7854.8 ₹

Annualized return

-26.76 %

Momentum equity curve on Gland Pharma Limited

The following chart shows the equity curve of the two momentum strategies applied to Gland Pharma Limited:

Gland Pharma Limited momentum equity

Note: the dividends potentially given by Gland Pharma Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Gland Pharma Limited

The following chart shows the employed capital evolution of the two momentum strategies on Gland Pharma Limited since the beginning:

Gland Pharma Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250₹, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000₹.


Buy the dip strategy result on Gland Pharma Limited

Buy the dip entry openings on Gland Pharma Limited

Gland Pharma Limited

The performance achieved by the robo-advisor on Gland Pharma Limited is 0%. That represents 0.0$ of latent gain with 0.0₹ of employed capital. The following chart shows Gland Pharma Limited stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Gland Pharma Limited, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 ₹

Invested capital

0.0 ₹

Annualized return

-0.0 %

Equity curve of the strategy applied to Gland Pharma Limited

The following chart shows the result of the investment strategy applied to Gland Pharma Limited:

Gland Pharma Limited

Note: the dividends potentially given by Gland Pharma Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Gland Pharma Limited

The following chart shows the employed capital evolution since the beginning of the investment strategy on Gland Pharma Limited:

Gland Pharma Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Gland Pharma Limited

In this section, I will compare the three previous investment strategies applied to Gland Pharma Limited.

Equity curve comparison on Gland Pharma Limited

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Gland Pharma Limited investment strategy comparison

Employed capital comparison on Gland Pharma Limited

Gland Pharma Limited investment comparison

Performance comparison on Gland Pharma Limited

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -10.82% -1115.9₹ 10313.0₹ -8.32%
Momentum 1 quarter -7.76% -773.45₹ 9970.55₹ -7.32%
Momentum 2 quarters -21.94% -1723.4₹ 7854.8₹ -26.76%
Non-directional 0% 0.0₹ 0.0₹ -0.0%
Annualized return comparison

Automatic investment

-8.32 %

Momentum 1Q

-26.76 %

Momentum 2Q

-26.76 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Gland Pharma Limited:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Gland Pharma Limited and the other stocks. There may be false positives or some missing correlated stocks. If the price of Gland Pharma Limited does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Gland Pharma Limited
Country India
City Hyderabad
Address Plot No. 11 & 84, TSIIC Phase: IV
Phone 91 84 5569 9999
Website www.glandpharma.com
FullTime employees 4638
Industry Drug Manufacturers—General
Sector Healthcare
Exchange XNSE
Ticker GLAND.XNSE
Market

Gland Pharma Limited ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown